MONTREAL, March 30, 2026 (GLOBE NEWSWIRE) — TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced that it will release its financial results for the first quarter ended March 31, 2026 via news release on Monday, April 27, 2026 after market close. The company will host a webcast with Alain Bédard, Chairman, President and Chief Executive Officer, and David Saperstein, Chief Financial Officer, on Monday, April 27, 2026 at 5:00 PM Eastern Time, to discuss results. Webcast Details:Date: Monday, April 27, 2026 Time: 5:00 PM Eastern Time Live webcast & replay: Presentations & Reports within the Investors section of the Company website. Alternatively for the live webcast visit webcast.ABOUT TFI INTERNATIONAL TFI International Inc. is a North American...

BURLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) — Progress Software (Nasdaq: PRGS), a member of the Russell 2000 Index, today announced its financial results for the fiscal first quarter 2026, which ended on February 28, 2026. Progress is the trusted provider of AI-powered digital experience and infrastructure software. The company’s earnings release and a supplemental slide presentation can be accessed via the Investor Events & Presentations link on the Progress Investor Relations webpage. Progress will host a conference call today at 5:00 p.m. ET to discuss its results and outlook. Conference Call DetailsA live webcast of the call will be available using this link. To access the conference call by phone, please use this link to retrieve dial-in details. To avoid delays, we encourage participants to dial in 15 minutes...

RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its financial results for the full year and fourth quarter ended December 31, 2025, and is providing a business update to shareholders. Shaun Bagai, Chief...

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populations Anticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026BOSTON, March 30, 2026 (GLOBE NEWSWIRE) — Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) applications for the Company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in several solid tumor types including prostate...

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transitioned to a clinical-stage neurology company with six clinical sites activated in Phase 1/2 STAND study in chronic neuropathic pain Announced in April, third neurology capsid license agreement, this time with Eli Lilly, to deliver genomic medicines for up to five central nervous system disease targets Raised over $130 million in funding since start of 2025 through non-dilutive...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet with Cash, Cash Equivalents and Short-Term Investments of Approximately $238.3 Million as of December 31, 2025, and Anticipated Runway into Second Half 2027 BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies...

CAMARILLO, Calif., March 30, 2026 (GLOBE NEWSWIRE) — Qualstar Corporation (OTC: QBAK), a trusted provider of scalable data storage and high-efficiency power solutions, today reported financial results for the quarter ended December 31, 2025. 2025 and Recent HighlightsWe achieved 9% year-over-year revenue growth in our Data Storage business. We recently launched the Q1000+ Powered by Orion, an enterprise tape library storage solution designed to be Simply Reliable™, offering superior performance and scalability for short-term backup, disaster recovery, and long-term archiving requirements. We hold over $2.8 million in cash, cash equivalents, and marketable securities, with no outstanding debt.Management Commentary “Despite a nearly $1.9 million decline in our Power Supply business and a slower fourth quarter overall,...

Financial Press Release : Annual results 2025   Reims, March 30, 2026 The Board of Directors of Maison Pommery & Associés met on March 30, 2026, under the chairmanship of Mr. Paul François Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the 2025 fiscal year.Consolidated data 31/12/2025*(M€) 31/12/2024(M€) Change(M€) Change(%)Turnover 293.2 304.0 -10.8 -3.6%Current Operating Income 20.0 35.7 -15.7 -44.1%Operating Income 64.1 35.1 +29.0 +82.5%Financial Result -32.6 -33.5 -0.9  Net Income 31.9 0.8 +31.0 +3751.9%Attributable to equity holders of the parent 32.0 0.9 +31.1 +3393.9%*The process of auditing and issuing the audit report for the certification of the consolidated accounts is underway. Business activity: market share gains in a contracting market Maison...

Please find attached the annual report (ESEF format) in English, for information only. The French version is the official one.Attachmentsolutions30-2025-12-31-en

2025 Annual Results Strong Revenue Growth in 2025: up 14% with Subscriptions up 20% Record Profitability: EBITDA up 22% to €13.4 million, Representing 22% of Revenue (+2 pts) Operating Leverage Confirmed: Net Profit of €9.0 million, up 14% March 30, 2026 | Sidetrade (Euronext Growth: ALBFR), the AI platform dedicated to Order-to-Cash, today announces its 2025 annual results, achieving a new all-time high in profitability despite a challenging macroeconomic environment: revenue growth of 14% at constant currency (12% on reported basis), EBITDA up 22% to €13.4 million, representing 22% of revenue, and net profit of €9.0 million (14%).Sidetrade (€m) 2025 2024 VariationRevenue 61.4 55.0 +12%of which Subscriptions 53,5 45,5 +18%Gross Margin 47.4 43.1 +10%as a % of Revenue 77% 78%         EBITDA* 13.4 11.0 +22%as a %...